Relay Therapeutics (RLAY) Upgraded by Oppenheimer, Price Target Set at $14
Relay Therapeutics (RLAY) received a significant upgrade from Oppenheimer today, elevating its rating from "Perform" to "Outperform." Analyst Matthew Biegler announced a new price target of $14.00 for the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.